Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.32 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097729 | 0.74 | MIF (0.44) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL9899343 | 0.74 | MIF (0.44) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL9898720 | 0.69 | MIF (0.40) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL1255910 | 0.67 | ALDH1A1 (0.57) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL11345168 | 0.65 | — | — | |
| Benzoquinone SCHEMBL10506648 | 0.65 | ALDH1A1 (1.00) | ALDH1A1BCHEPOLBMAOAACHE | |
| Benzoquinone SCHEMBL3208089 | 0.65 | — | — | |
| Benzoquinone SCHEMBL18103 | 0.65 | — | — | |
| Benzoquinone SCHEMBL460082 | 0.65 | ALDH1A1 (1.00) | ALDH1A1BCHEPOLBMAOAACHE | |
| Benzoquinone SCHEMBL30679171 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160866-B2 | Biomaterials for delivery of blood extracts and methods of using same | MOSAIC BIOSCIENCES, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2537539-B1 | Polymeric Tissue Sealant | KUROS BIOSURGERY AG (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-10016505-B2 | Biomaterials for delivery of blood extracts and methods of using same | MOSAIC BIOSCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016505-B2 | Biomaterials for delivery of blood extracts and methods of using same | MOSAIC BIOSCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2311895-B1 | BIOMATERIALS FORMED BY NUCLEOPHILIC ADDITION REACTION TO CONJUGATED UNSATURATED GROUPS | Eidgenössische Technische Hochschule Zürich (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9180222-B2 | Polymeric tissue sealant | KUROS BIOSURGERY AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9180222-B2 | Polymeric tissue sealant | KUROS BIOSURGERY AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150133579-A1 | Polymeric Tissue Sealant | KUROS BIOSURGERY AG (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133579-A1 | Polymeric Tissue Sealant | KUROS BIOSURGERY AG (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8961947-B2 | Polymeric tissue sealant | KUROS BIOSURGERY AG (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | UNIVERSITAT ZURICH (CH) | 2009-04-16 | — | — | US | disclosed |
| WO-2008125655-A1 | POLYMERIC TISSUE SEALANT | KUROS BIOSURGERY AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-20080253987-A1 | Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability | KUROS BIOSURGERY AG | 2008-10-16 | — | — | US | disclosed |
| US-20080253987-A1 | Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability | KUROS BIOSURGERY AG | 2008-10-16 | — | — | US | disclosed |
| US-7413739-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2008-08-19 | — | — | US | disclosed |
| US-7413739-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070264227-A1 | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH | 2007-11-15 | — | — | US | disclosed |
| US-20070264227-A1 | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH | 2007-11-15 | — | — | US | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160866-B2 | Biomaterials for delivery of blood extracts and methods of using same | PDGFA, PGF, MATR3 | ALDH1A1 3646/4885BCHE 2414/4885POLB 2996/4885 |
| US-10016505-B2 | Biomaterials for delivery of blood extracts and methods of using same | PDGFA, PGF, MATR3 | ALDH1A1 3646/4885BCHE 2414/4885POLB 2996/4885 |
| US-20070264227-A1 | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration | FGF2, EPCAM, FGF1 | ALDH1A1 1296/4885BCHE 3628/4885POLB 883/4885 |
| US-20080253987-A1 | Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability | PAM, BMP6, PTGER1 | ALDH1A1 3596/4885BCHE 2599/4885POLB 2799/4885 |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | PAICS, COASY, LIPA | ALDH1A1 409/4885BCHE 345/4885POLB 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.